title: A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients.
abstract: OBJECTIVE
  To evaluate the efficacy of topical aldose reductase inhibitor CT-112 (5-[3-ethoxy-4-pentyloxyphenyl]-2,4-thiazolidinedione) on corneal epithelial barrier function in diabetic patients.
  
  
  METHODS
  This was a prospective, randomised, double masked placebo controlled study. 34 eyes of 34 diabetic patients were randomly assigned treatment with 0.25% eye drops of CT-112 (n = 22) or a placebo (n = 12) four times a day for 8 weeks. Corneal fluorescein staining and corneal sensation were examined before treatment as well as 4 and 8 weeks after administration. Corneal epithelial permeability to fluorescence was measured with an anterior fluorophotometer.
  
  
  RESULTS
  Average scores of superficial punctate keratopathy and corneal sensitivity did not differ significantly between the two groups at any time. Whereas average fluorescein concentrations did not differ significantly for the CT-112 and placebo groups before treatment, they did differ significantly 4 and 8 weeks after treatment (4 weeks, p = 0.0327; 8 weeks, p = 0.0143).
  
  
  CONCLUSIONS
  The topical aldose reductase inhibitor, CT-112 improves the corneal epithelial barrier function in diabetic patients.
authors.affiliation: Meiwakai Medical Foundation, Miyata Eye Hospital, Miyakonojo, Miyazaki, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Nakahara
authors.forename: K
authors.initials: K
authors.lastname: Miyata
authors.forename: S
authors.initials: S
authors.lastname: Otani
authors.forename: T
authors.initials: T
authors.lastname: Miyai
authors.forename: R
authors.initials: R
authors.lastname: Nejima
authors.forename: S
authors.initials: S
authors.lastname: Yamagami
authors.forename: S
authors.initials: S
authors.lastname: Amano
mesh_terms: D000368:Aged; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D003320:Corneal Ulcer / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004311:Double-Blind Method; D019573:Epithelium, Corneal / Q000378:metabolism / Q000503:physiopathology; D019793:Fluorescein; D015590:Fluorophotometry; D006801:Humans; D008875:Middle Aged; D009883:Ophthalmic Solutions; D010539:Permeability; D011446:Prospective Studies; D012684:Sensory Thresholds; D018709:Statistics, Nonparametric; D045162:Thiazolidinediones / Q000008:administration & dosage* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D009883:Ophthalmic Solutions; D045162:Thiazolidinediones; C051003:risarestat; D000449:Aldehyde Reductase; D019793:Fluorescein
references.citation: Invest Ophthalmol Vis Sci. 2000 Feb;41(2):362-8
references.pmid: 10670463
references.citation: Trans Am Ophthalmol Soc. 1981;79:180-99
references.pmid: 7342400
references.citation: Br J Ophthalmol. 2002 Aug;86(8):860-3
references.pmid: 12140204
references.citation: Arch Ophthalmol. 2003 Nov;121(11):1537-9
references.pmid: 14609908
references.citation: Cornea. 2004 Jan;23(1):35-7
references.pmid: 14701955
references.citation: Am J Ophthalmol. 1978 May;85(5 Pt 1):651-5
references.pmid: 655244
references.citation: Arch Ophthalmol. 1978 Aug;96(8):1401-3
references.pmid: 678179
references.citation: Arch Ophthalmol. 1979 Jun;97(6):1076-8
references.pmid: 444136
references.citation: Metabolism. 1979 Apr;28(4 Suppl 1):462-9
references.pmid: 45423
references.citation: Diabetes. 1984 Jun;33(6):562-6
references.pmid: 6427040
references.citation: Ann Intern Med. 1984 Jul;101(1):82-91
references.pmid: 6203454
references.citation: Arch Ophthalmol. 1988 Jul;106(7):916-9
references.pmid: 3390054
references.citation: J Biol Chem. 1989 Mar 5;264(7):3674-9
references.pmid: 2537288
references.citation: Graefes Arch Clin Exp Ophthalmol. 1989;227(2):142-4
references.pmid: 2721983
references.citation: Nippon Ganka Gakkai Zasshi. 1994 Jul;98(7):641-7
references.pmid: 8067296
references.citation: Am J Ophthalmol. 1995 Mar;119(3):288-94
references.pmid: 7872388
references.citation: Cornea. 1995 Sep;14(5):485-9
references.pmid: 8536461
references.citation: Ophthalmology. 1996 Jan;103(1):50-7
references.pmid: 8628561
references.citation: Cornea. 1996 Jul;15(4):368-75
references.pmid: 8776562
references.citation: Biochem Biophys Res Commun. 1996 Nov 12;228(2):539-43
references.pmid: 8920948
references.citation: Curr Eye Res. 1997 Jun;16(6):595-9
references.pmid: 9192169
references.citation: Br J Ophthalmol. 1997 Jul;81(7):533-6
references.pmid: 9290362
references.citation: FEBS Lett. 1998 Dec 11;441(1):116-20
references.pmid: 9877177
references.citation: Cornea. 1999 Sep;18(5):559-64
references.pmid: 10487430